OTC:BRGX
BIOREGENX, INC.
A clinical-stage biopharmaceutical company advancing proprietary oncology and rare disease therapies with recent revenue generation and significant cash flow burn.
Key Metrics
Investment Thesis
Bull Case
Bull investors see BRGX as a high-risk, high-reward opportunity to own a potential blockbuster therapy before it hits the market. The recent generation of $2.3M revenue indicates early commercial traction or strategic partnerships that could validate the technology platform. If clinical trials succeed, the current low valuation based on negative earnings could offer significant upside upon successful product launches.
Bear Case
Bear investors should avoid BRGX due to its deep financial hole with a $35.6M deficit and operating cash burn exceeding $300k annually. The company lacks profitability and relies entirely on external financing, which may dry up if market conditions worsen or clinical results are delayed. With total liabilities nearing $4M and no current assets to cover short-term obligations, the risk of dilution or bankruptcy is substantial.
About BIOREGENX, INC.
BIOREGENX, INC. (BRGX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs in oncology and rare diseases. The company operates primarily within the U.S. and international markets, leveraging its proprietary technology platform to advance preclinical candidates toward clinical trials. With a recent revenue spike to $2.3M in 2024, the firm is actively transitioning from R&D heavy investment phases to early commercialization efforts.
Analysis
Management Discussion
Management is navigating a critical inflection point where recent operational losses of $23.1M have widened considerably from prior years, signaling intense investment in pipeline development. While cash flow from operations remains negative, substantial financing inflows suggest management's strategy to leverage external capital to sustain R&D efforts and bridge the path to commercialization. The balance sheet shows a precarious position with total liabilities of $3.9M against only $508k in assets, highlighting the need for continued successful fundraising.
Industry Overview
The biotechnology industry is characterized by high failure rates, long development cycles, and significant capital requirements for bringing drugs to market. Companies like BIOREGENX operate in a competitive landscape where intellectual property protection and clinical trial success are paramount for survival. Recent trends show a shift towards partnering with larger pharmaceutical companies to share the financial burden of late-stage development.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $42.2K | $22.2K | $2.3M |
| Cost of Revenue | $0 | $0 | $681.7K |
| Gross Profit | $42.2K | $22.2K | $1.7M |
| Operating Expenses | $120.5K | $131.9K | $24.4M |
| Operating Income | $-78.3K | $-109.7K | $-22.8M |
| R&D | — | — | $0 |
| G&A | — | — | $5.9M |
| Stock-Based Comp | — | — | $2.9M |
| D&A | — | — | $2.2M |
| Other OpEx | — | — | $18.6M |
| Non-Operating Income | $0 | $-461.5K | $0 |
| Interest Expense | — | $8.3K | — |
| Pre-Tax Income | $-78.3K | $-571.2K | $-22.8M |
| Income Tax | $0 | $0 | $290.7K |
| Continuing Ops | $-78.3K | $-571.2K | $-23.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-78.3K | $-571.2K | $-23.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-78.3K | $-571.2K | $-23.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $676 | $0 | $307.8K |
| Cash & Equivalents | — | — | $58.4K |
| Accounts Receivable | — | — | $15.0K |
| Inventory | — | — | $111.1K |
| Prepaid Expenses | — | — | $123.3K |
| Other Current Assets | — | — | $0 |
| Long-Term Assets | $58.5K | $31.6K | $200.7K |
| PP&E (Net) | — | — | $200.7K |
| Other LT Assets | — | — | $0 |
| Total Assets | $59.1K | $31.6K | $508.5K |
| Current Liabilities | $64.9K | $253.6K | $3.6M |
| Accounts Payable | — | — | $427.5K |
| Current Debt | $4.2K | $200.0K | $883.3K |
| Other Current Liab | $60.7K | $53.6K | $1.9M |
| Long-Term Liabilities | $195.8K | $0 | $254.6K |
| Long-Term Debt | $195.8K | $0 | $254.6K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $260.7K | $253.6K | $3.9M |
| Shareholders' Equity | $-201.5K | $-222.0K | $-3.4M |
| Paid-In Capital | $2.4M | $3.0M | $31.0M |
| Retained Earnings | $-2.9M | $-3.5M | $-35.6M |
| AOCI | — | — | $2.0K |
| Total L&E | $59.1K | $31.6K | $508.5K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-78.3K | $-571.2K | $-23.1M |
| Non-Cash Adjustments | $5.9K | $549.3K | $22.9M |
| Working Capital Changes | $7.7K | $8.5K | $-157.2K |
| Cash from Operations | $-64.7K | $-13.3K | $-324.1K |
| Capital Expenditures | — | — | $189.4K |
| Cash from Investing | $0 | $0 | $-187.9K |
| Cash from Financing | $41.0K | $12.7K | $442.1K |
| FX Effect | $0 | $0 | $3.0K |
| Net Change in Cash | $-23.7K | $-676 | $-67.0K |
| Beginning Cash | $24.4K | $676 | $125.4K |
| Ending Cash | $676 | $0 | $58.4K |
Frequently Asked Questions
How does BIOREGENX, INC. make money?
The company's financials indicate a primary focus on Research and Development (R&D) with zero recorded R&D spend in the dataset but high operating expenses, suggesting internal drug discovery programs. Revenue streams are currently driven by early-stage licensing or collaboration agreements given the $2.3M revenue against minimal receivables. The balance sheet reflects a capital-intensive model with significant current liabilities ($3.6M) and long-term debt obligations typical of pre-revenue biotech firms.
What are the main risks for BRGX?
The company faces severe financial distress risks with a retained earnings deficit of $35.6M and negative net income of $23.1M in 2024. Operational risk is high due to the clinical-stage nature of the business where product approval timelines are uncertain and costly. Liquidity concerns are exacerbated by negative operating cash flow (-$324,148) and a current liability load significantly higher than assets. The lack of diversified revenue streams makes the stock highly volatile and dependent on future partnership deals or successful drug approvals.
What is BRGX's competitive advantage?
BIOREGENX possesses a differentiated proprietary technology platform targeting specific unmet needs in oncology and rare disease markets. The company maintains strategic intellectual property portfolios that provide potential first-in-class or best-in-class therapeutic options. Strong cash flow from financing activities ($442,119) indicates active investor confidence and successful capital raising to fund pipeline advancement.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.